ALVOTECH SA (ALVO) Stock Price & Overview
NASDAQ:ALVO • LU2458332611
Current stock price
The current stock price of ALVO is 3.65 USD. Today ALVO is up by 0.83%. In the past month the price decreased by -12.26%. In the past year, price decreased by -57.06%.
ALVO Key Statistics
- Market Cap
- 1.138B
- P/E
- 52.14
- Fwd P/E
- 8.78
- EPS (TTM)
- 0.07
- Dividend Yield
- N/A
ALVO Stock Performance
ALVO Stock Chart
ALVO Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ALVO. When comparing the yearly performance of all stocks, ALVO is a bad performer in the overall market: 93.23% of all stocks are doing better.
ALVO Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ALVO. There are concerns on the financial health of ALVO while its profitability can be described as average.
ALVO Earnings
On March 18, 2026 ALVO reported an EPS of -0.37 and a revenue of 168.90M. The company missed EPS expectations (-706.1% surprise) and beat revenue expectations (3.53% surprise).
ALVO Forecast & Estimates
12 analysts have analysed ALVO and the average price target is 8.08 USD. This implies a price increase of 121.23% is expected in the next year compared to the current price of 3.65.
For the next year, analysts expect an EPS growth of 493.79% and a revenue growth 11.79% for ALVO
ALVO Groups
Sector & Classification
ALVO Financial Highlights
Over the last trailing twelve months ALVO reported a non-GAAP Earnings per Share(EPS) of 0.07. The EPS increased by 108.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 4.74% | ||
| ROA | 1.88% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ALVO Ownership
ALVO Latest News, Press Relases and Analysis
ALVO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ALVO
Company Profile
Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focused on the development and manufacture of biosimilar medicines for patients globally. The company is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). The company has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Company Info
IPO: 2020-11-09
ALVOTECH SA
9, Rue De Bitbourg
Luxembourg LU
Employees: 1012
Phone: 35244224500
ALVOTECH SA / ALVO FAQ
What does ALVOTECH SA do?
Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focused on the development and manufacture of biosimilar medicines for patients globally. The company is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). The company has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
What is the stock price of ALVOTECH SA today?
The current stock price of ALVO is 3.65 USD. The price increased by 0.83% in the last trading session.
Does ALVO stock pay dividends?
ALVO does not pay a dividend.
How is the ChartMill rating for ALVOTECH SA?
ALVO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Which stock exchange lists ALVO stock?
ALVO stock is listed on the Nasdaq exchange.
What is the employee count for ALVO stock?
ALVOTECH SA (ALVO) currently has 1012 employees.
Can you provide the ownership details for ALVO stock?
You can find the ownership structure of ALVOTECH SA (ALVO) on the Ownership tab.